Respiratory Medicine and Research最新文献

{"title":"Venous thromboembolism in sarcoidosis: Mere comorbidity or catalyst for disease evolution?","authors":"Mitja Jevnikar, Géraldine Poenou, David Montani, Laurent Bertoletti","doi":"10.1016/j.resmer.2023.101062","DOIUrl":"10.1016/j.resmer.2023.101062","url":null,"abstract":"","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"85 ","pages":"Article 101062"},"PeriodicalIF":2.3,"publicationDate":"2023-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135456160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"U-net convolutional neural network applied to progressive fibrotic interstitial lung disease: Is progression at CT scan associated with a clinical outcome?","authors":"Xavier Guerra ,&nbsp;Simon Rennotte ,&nbsp;Catalin Fetita ,&nbsp;Marouane Boubaya ,&nbsp;Marie-Pierre Debray ,&nbsp;Dominique Israël-Biet ,&nbsp;Jean-François Bernaudin ,&nbsp;Dominique Valeyre ,&nbsp;Jacques Cadranel ,&nbsp;Jean-Marc Naccache ,&nbsp;Hilario Nunes ,&nbsp;Pierre-Yves Brillet","doi":"10.1016/j.resmer.2023.101058","DOIUrl":"10.1016/j.resmer.2023.101058","url":null,"abstract":"<div><h3>Background</h3><p>Computational advances in artificial intelligence have led to the recent emergence of U-Net convolutional neural networks (CNNs) applied to medical imaging. Our objectives were to assess the progression of fibrotic interstitial lung disease (ILD) using routine CT scans processed by a U-Net CNN developed by our research team, and to identify a progression threshold indicative of poor prognosis.</p></div><div><h3>Methods</h3><p>CT scans and clinical history of 32 patients with idiopathic fibrotic ILDs were retrospectively reviewed. Successive CT scans were processed by the U-Net CNN and ILD quantification was obtained. Correlation between ILD and FVC changes was assessed. ROC curve was used to define a threshold of ILD progression rate (PR) to predict poor prognostic (mortality or lung transplantation). The PR threshold was used to compare the cohort survival with Kaplan Mayer curves and log-rank test.</p></div><div><h3>Results</h3><p>The follow-up was 3.8 ± 1.5 years encompassing 105 CT scans, with 3.3 ± 1.1 CT scans per patient. A significant correlation between ILD and FVC changes was obtained (<em>p</em> = 0.004, ρ = -0.30 [95% CI: -0.16 to -0.45]). Sixteen patients (50%) experienced unfavorable outcome including 13 deaths and 3 lung transplantations. ROC curve analysis showed an aera under curve of 0.83 (<em>p</em> &lt; 0.001), with an optimal cut-off PR value of 4%/year. Patients exhibiting a PR ≥ 4%/year during the first two years had a poorer prognosis (<em>p</em> = 0.001).</p></div><div><h3>Conclusions</h3><p>Applying a U-Net CNN to routine CT scan allowed identifying patients with a rapid progression and unfavorable outcome.</p></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"85 ","pages":"Article 101058"},"PeriodicalIF":2.3,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135371043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics, management, and healthcare resources of patients with advanced non–small-cell lung cancer surviving 5 years after nivolumab treatment initiation: A national database analysis","authors":"Jean-Baptiste Assié ,&nbsp;Valentine Grumberg ,&nbsp;Dorothée Reynaud ,&nbsp;Anne-Françoise Gaudin ,&nbsp;Alexandre Batisse ,&nbsp;Ronan Jolivel ,&nbsp;Baptiste Jouaneton ,&nbsp;François-Emery Cotté ,&nbsp;Christos Chouaïd","doi":"10.1016/j.resmer.2023.101051","DOIUrl":"10.1016/j.resmer.2023.101051","url":null,"abstract":"<div><h3>Background</h3><p>Data on long-term survivors with advanced non-small-cell lung cancer (NSCLC) treated with nivolumab are available from randomized trials. Characteristics, management, and healthcare resources of those patients need to be confirmed with real-world data.</p></div><div><h3>Methods</h3><p>The UNIVOC retrospective observational study included all patients with advanced NSCLC recorded in the French national hospital database starting nivolumab in 2015 and followed them until December 2020. The Kaplan-Meier method estimated the overall survival (OS). A machine learning approach identified patients with similar treatment sequences.</p></div><div><h3>Results</h3><p>Within the 3,050 patients who had nivolumab initiation,5-year OS rate was 14.6 % (95 %CI 13.3 %–16.2 %). In total, data covering at least 5 years of follow-up were retrieved for 231 surviving patients. Survivors were younger, often female and had fewer comorbidities than non-survivors. Three clusters of patients with different nivolumab treatment durations were identified: 1/ Continuous nivolumab treatment; 2/ Long period of nivolumab treatment followed by chemotherapy or no treatment; 3/ Short period of nivolumab treatment then chemotherapy or no treatment. At 5 years, 61.0 % of survivors were no longer receiving systemic therapy, 26.4 % were treated with nivolumab, 8.7 % chemotherapy, and 3.9 % other immunotherapies. Among 5-y survivor patients, the average number of hospitalisations per patient decreased from 23.4 to 12.8 between the 1st and the 5th year. In the 5th year, 46 % of patients had no more hospitalization for lung cancer.</p></div><div><h3>Conclusions</h3><p>This large nationwide study confirms the long-term benefit of nivolumab treatment for advanced NSCLC patients in the real-world setting, with a 5-year survival rate similar to that reported in clinical trials.</p></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"84 ","pages":"Article 101051"},"PeriodicalIF":2.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590041223000636/pdfft?md5=59c8da3e00597bad7c492a390564d1dc&pid=1-s2.0-S2590041223000636-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66784497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physical activity and sedentary behaviour in patients admitted with COPD: Associated factors","authors":"Cristóbal Esteban ,&nbsp;Ane Antón-Ladislao ,&nbsp;Amaia Aramburu ,&nbsp;Leyre Chasco ,&nbsp;Miren Orive ,&nbsp;Patricia Sobradillo ,&nbsp;Lorena López-Roldan ,&nbsp;Alberto Jiménez-Puente ,&nbsp;Javier de Miguel ,&nbsp;Ignacio García-Talavera ,&nbsp;José M. Quintana ,&nbsp;the ReEPOC-REDISSEC group","doi":"10.1016/j.resmer.2023.101052","DOIUrl":"10.1016/j.resmer.2023.101052","url":null,"abstract":"<div><h3>Aim</h3><p>To establish amongst a cohort of patients admitted with Chronic Obstructive Pulmonary Disease which factors were associated with their level of Physical Activity and Sedentary Behavior prior to the admission event.</p></div><div><h3>Methods</h3><p><span>Prospective observational cohort study. Nine Spanish hospitals participated. Patients were recruited consecutively. Variables relating to the patients' clinical baseline status were recorded, including the COPD Assessment test, the HADS anxiety-depression test, comorbidities and the Yale Physical Activity Survey. Data relating to admission and up to two months </span>after discharge were also recorded.</p></div><div><h3>Results</h3><p><span>1638 COPD patients were studied, with a mean age of 72.39 (SD 10.33), 76.56 % male, FEV1<span> 49.41 % (SD19.19), Charlson index 2. The level of PA at baseline was 30.79 points (SD 22.43). Multivariable </span></span>linear regression analysis<span><span> identified the following as being associated with low PA: older age, obesity, higher level of hemoglobin, lower score of Barthel index, which means disability, health related </span>quality of life (EuroQoL-5d and CAT) and dyspnea. Variables associated with sedentary behavior were: older age, presence of obstructive apnea syndrome, higher disability, presence of depressive symptoms and dyspnea.</span></p></div><div><h3>Conclusions</h3><p>In a cohort of hospitalized COPD patients, we have found several variables, some of them modifiable, associated with physical activity/inactivity and sedentary behavior.</p></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"84 ","pages":"Article 101052"},"PeriodicalIF":2.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66784498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pulmonary arterial hypertension and COVID-19: Piecing the puzzle","authors":"Fida Charif ,&nbsp;Fatima Dakroub ,&nbsp;Imad Bou Akl ,&nbsp;Mithum Kularatne ,&nbsp;David Montani","doi":"10.1016/j.resmer.2023.101053","DOIUrl":"https://doi.org/10.1016/j.resmer.2023.101053","url":null,"abstract":"<div><p><span><span>COVID-19 remains a health care concern despite the end of the pandemic. Patients with cardiovascular disease (CVD) are at a higher risk for developing severe COVID-19 complications. Studies investigating the COVID-19 clinical characteristics in pulmonary arterial hypertension (PAH) patients have reported discordant conclusions so far. In this review, we summarize the literature pertaining to the clinical presentation of COVID-19 </span>in patients<span> with PAH. In addition, we discuss common pathological aspects and disease mechanisms between PAH and COVID-19. We present an overview of the different types of PAH-approved therapy and their potential utilization as a treatment in the context of COVID-19. Moreover, we summarize the </span></span>clinical trials<span> that assessed the safety and efficiency of PAH-approved drugs in COVID-19 patients. Finally, we conclude with proposals for prospective research studies.</span></p></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"84 ","pages":"Article 101053"},"PeriodicalIF":2.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91956662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The benefits of COVID lockdowns on respiratory health: What factors may have contributed to the decline in hospital admissions for cystic fibrosis?","authors":"Rebecca C. Robey ,&nbsp;Orlagh Crozier ,&nbsp;Arran Frame ,&nbsp;Katrina Martin ,&nbsp;Philip Ashcroft ,&nbsp;Nizhat Iqbal ,&nbsp;Peter J. Barry ,&nbsp;Andy Jones ,&nbsp;Shazaad Ahmad ,&nbsp;Alexander Horsley","doi":"10.1016/j.resmer.2023.101061","DOIUrl":"10.1016/j.resmer.2023.101061","url":null,"abstract":"","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"84 ","pages":"Article 101061"},"PeriodicalIF":2.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590041223000739/pdfft?md5=48d96c0a85f09bcc2831dfa0571f5913&pid=1-s2.0-S2590041223000739-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135411861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between persistent dyspnea and psychological distress in COVID-19 survivors. A cross-sectional evaluation at 11 months after hospitalization","authors":"Luca Bodini ,&nbsp;Giulia Sartori ,&nbsp;Chiara Bonetto ,&nbsp;Michele Ranzolin ,&nbsp;Anna Bertuetti ,&nbsp;Francesca Miscetti ,&nbsp;Antonio Lasalvia ,&nbsp;Ernesto Crisafulli","doi":"10.1016/j.resmer.2023.101067","DOIUrl":"10.1016/j.resmer.2023.101067","url":null,"abstract":"","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"84 ","pages":"Article 101067"},"PeriodicalIF":2.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135715040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term survival comparison between the first and second waves among 265 critical COVID-19 patients admitted to the ICU: A retrospective cohort study","authors":"Nour-El-Imane Taghboulit ,&nbsp;Claire Andrejak ,&nbsp;Yazine Mahjoub ,&nbsp;Bénédicte Toublanc ,&nbsp;Isabelle Mayeux ,&nbsp;Julia Delomez ,&nbsp;Marie Mercier ,&nbsp;Pauline Leriche ,&nbsp;Julien Maizel ,&nbsp;Hervé Dupont ,&nbsp;Vincent Jounieaux ,&nbsp;Damien Basille","doi":"10.1016/j.resmer.2023.101057","DOIUrl":"10.1016/j.resmer.2023.101057","url":null,"abstract":"<div><h3>Backgroud</h3><p>Management of severe COVID-19 patients admitted to ICU considerably evolved during the first months of the pandemic. It is unclear, however, whether these changes improved long-term survival of these critically ill patients.</p></div><div><h3>Methods</h3><p>We conducted a retrospective cohort study in adults with COVID-19 pneumonia admitted to a French ICU between February 2020 and January 2021, a timeframe that covered the first two waves of the pandemic. Primary outcome was to compare long-term survival between the first and second waves. Survival predictor were identified using a Cox proportional-hazards model.</p></div><div><h3>Results</h3><p><span>We included 265 patients in the cohort: 140 (52.8 %) and 125 (47.2 %) belonging to the first and second waves, respectively. Baseline characteristics of the patients were similar between the two waves. During W2, use of early corticotherapy increased (86.4% vs. 17.8 %; </span><em>p</em> &lt;0.001), as well as high-flow oxygen therapy use (68.5% vs<em>.</em> 37.4 %; <em>p</em><span>&lt;0.001). Need for invasive mechanical ventilation decreased (49.6% vs. 72.9 %; </span><em>p</em> &lt;0.001) and ICU length of stay was shorter (11 [6–22] vs 19 [8–32]days; <em>p</em><span> = 0.008). ICU mortality was 32.8 % without significant difference between waves. Survival analysis revealed that 3 variables were independently associated with a worse long-term prognosis: a higher SAPS II score (1.05 [1.04–1.06]; </span><em>p</em>&lt;0.001), a higher age (1.05 [1.01–1.08]; <em>p</em> = 0.005) and admission during W2 (2.22 [1.15–4.28]; <em>p</em> = 0.017).</p></div><div><h3>Discussion</h3><p>Despite substantial changes on management of severe COVID-19 patients, we observed a decreased long-term survival among patients admitted during the second wave. We also noted a shorter ICU length of stay.</p></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"84 ","pages":"Article 101057"},"PeriodicalIF":2.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71427964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peripheral cellular biomarkers in bronchiectasis","authors":"Miguel Ángel Martínez-García,&nbsp;Grace Oscullo,&nbsp;Jose Daniel Gomez-Olivas","doi":"10.1016/j.resmer.2023.101063","DOIUrl":"10.1016/j.resmer.2023.101063","url":null,"abstract":"","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"84 ","pages":"Article 101063"},"PeriodicalIF":2.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135410455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term effect of tocilizumab on mortality, readmissions, persistent symptoms and lung function in SARS-CoV-2 patients 1 year after hospital discharge: A matched cohort study","authors":"Ignacio Cardona-Pascual PharmD ,&nbsp;Mercedes Pallero MD, PhD ,&nbsp;David Berlana PharmD, PhD ,&nbsp;Ana Villar MD, PhD ,&nbsp;Jose Bruno Montoro-Ronsano PharmD, PhD ,&nbsp;Cristina Berastegui MD, PhD","doi":"10.1016/j.resmer.2023.101064","DOIUrl":"10.1016/j.resmer.2023.101064","url":null,"abstract":"<div><h3>Background</h3><p><span>Tocilizumab<span> is presumed to be an effective and safe treatment for severe SARS-Cov-2, but its usefulness has not been investigated yet for long-term outcomes. This study aimed to evaluate the influence of tocilizumab on mortality </span></span>in patients with SARS-CoV-2 throughout the year following discharge.</p></div><div><h3>Methods</h3><p>A retrospective observational analysis was performed on electronic medical records<span> of patients with SARS-CoV2 who were discharged from our hospital after surviving the first wave in March-April 2020. Logistic regression was used to analyse the effect of tocilizumab on mortality, as the main outcome, and propensity-score analysis to further validate their effect. Secondary outcomes were readmissions, persistent symptoms and lung function evolution. Patients were selected by matching their individual propensity for receiving therapy with tocilizumab, conditional on their demographic and clinical variables.</span></p></div><div><h3>Results</h3><p>A total of 405 patients were included in the mortality study (33.6 % were treated with tocilizumab) and 390 were included in the assessment of persistent symptoms. After propensity-score analysis, no association between tocilizumab use and 1-year overall mortality was found (HR= 2.05, 95 % CI: 0.21–19.98). No differences regarding persistent symptoms (OR= 1.01 95 %CI 0.57–1.79), nor lung function parameters (forced vital capacity: coefficient -0.16 95 %CI -0.45 to 0.14) were found throughout the year follow-up between control and tocilizumab group.</p></div><div><h3>Conclusions</h3><p>The administration of tocilizumab in patients with SARS-CoV-2 did not show any effect on long-term mortality. Identically, no association were found regarding readmissions, persistent symptoms or lung function evolution and tocilizumab administration in our cohort of patients after 1 year follow-up.</p></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"84 ","pages":"Article 101064"},"PeriodicalIF":2.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135454748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}